Outcome of Restarted Sunitinib Treatment in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Trial and Combined Case Reports from Literature
- 178 Downloads
In practice it is still not clear whether a drug holiday in sunitinib (Su) treatment can be safety, without impairing the overall outcome of patients with metastatic renal cell carcinoma (mRCC). The aim was to retrospectively evaluate the outcome in patients who restarted Su after an interruption of ≥3 months and a combined analysis of case studies from literature. From 556 patients treated between January 2006 and March 2016 a group of 38 patients were selected whose treatment was interrupted for other reasons than disease progression. During interruption Su was restarted in case of RECIST-defined progression. The primary objective was the objective response (OR) and progression free survival (PFS) of baseline and restarted therapy. The secondary objective was the overall survival (OS) calculated from the start of baseline treatment. Multivariate survival analysis was also applied. The major causes of interruption were toxicity (39%) and patient’ choice (24%). Median duration of interruption was 7 (range 3–41) months. The OR of baseline and restarted treatment was 63% and 39%, respectively. After a median follow-up of 76 (95% CI 65–79) months the median PFS of baseline and restarted treatment was 21 (18–27) and 14 (10–18) months, respectively. The median OS was 61 (56–80) months. In multivariate analysis the lack of OR of restated treatment was an independent predictor of shorter PFS of restarted Su. According to our findings and also on combined case studies from literature restarted Su can be effective in selected cases of patients who progressed during treatment holiday.
KeywordsDrug holiday Overall survival Patient’s choice Progression-free survival Toxicity
This research has no funding support.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 4.Johannsen M, Staehler M, Ohlmann CH et al (2011) Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann Oncol 22:657–663. https://doi.org/10.1093/annonc/mdq437 CrossRefGoogle Scholar
- 6.Ornstein MC, Wood LS, Elson P et al (2017) A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma. J Clin Oncol 35:1764–1769. https://doi.org/10.1200/JCO.2016.71.1184
- 7.Johannsen M, Flörcken A, Bex A et al (2009) Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 55:1430–1438. https://doi.org/10.1016/j.eururo.2008.10.021 CrossRefGoogle Scholar
- 8.Miura Y, Fujii Y, Shimomura A et al (2014) Temporal cessation of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective study. Ann Oncol 25(Suppl.5):v46. https://doi.org/10.1093/annonc/mdu435.10
- 10.Bono P ESMO e-learning: renal cell cancer - clinical case study 1 and 2. http://oncologypro.esmo.org/content/download/22271/368712/file/Renal-Cell-Cancer-Bono.pdf
- 13.Calvo OF, Vázquez DD, López MR, Aparicio LM (2010) Renal cell carcinoma: complete response. Anti-Cancer Drugs 21(Suppl 1):S17–S18. https://doi.org/10.1097/01.cad.0000361531.59299.5a CrossRefGoogle Scholar
- 14.Paule B, Brion N (2010) Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases. Anticancer Res 30:5165–5168Google Scholar
- 17.van der Veldt AA, van den Eertwegh AJ, Boven E (2007) Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer. Ned Tijdschr Geneeskd 151:1142–1147Google Scholar
- 19.Kim H, Shoji S, Usui Y et al (2013) A case of complete response of multiple lung metastases of renal cell carcinoma with the flexible administration of sunitinib. Hinyokika Kiyo 59:7–10Google Scholar
- 22.Schmidinger M, Bojic A, Vogl UM et al (2009) Management of cardiac adverse events occurring with sunitinib treatment. Anticancer Res 29:1627–1629Google Scholar
- 25.Hammers HJ, Verheul HM, Salumbides B et al (2010) Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 9:1525–1535. https://doi.org/10.1158/1535-7163.MCT-09-1106 CrossRefGoogle Scholar
- 26.Collinson FJ, Gregory WM, McCabe C et al (2012) The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer. BMC Cancer 12:598. https://doi.org/10.1186/1471-2407-12-598 CrossRefGoogle Scholar